PE20091429A1 - 4-(4-ciano-2-tioaril)dihidropirimidinonas como inhibidores de la elastasa neutrofila humana (hne) - Google Patents
4-(4-ciano-2-tioaril)dihidropirimidinonas como inhibidores de la elastasa neutrofila humana (hne)Info
- Publication number
- PE20091429A1 PE20091429A1 PE2008002054A PE2008002054A PE20091429A1 PE 20091429 A1 PE20091429 A1 PE 20091429A1 PE 2008002054 A PE2008002054 A PE 2008002054A PE 2008002054 A PE2008002054 A PE 2008002054A PE 20091429 A1 PE20091429 A1 PE 20091429A1
- Authority
- PE
- Peru
- Prior art keywords
- cyane
- alkyl
- phenyl
- hne
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/10—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
SE REFIERE A DERIVADOS DE HIDROPIRIMIDINAS DE FORMULA (I), DONDE A Y E REPRESENTAN LOS DOS C-R7 O UNO DE LOS DOS MIEMBROS DEL ANILLO A Y E ES N Y EL OTRO ES C-R7; R7 ES H, F O CL; Z ES O o S; n ES 0, 1 O 2; R1 ES ALQUILO (C1-C6) OPCIONALMENTE SUSTITUIDO CON HIDROXILO, ALCOXI (C1-C4), AMINO, ENTRE OTROS; R2 ES H, F O CL; R3 ES CIANO O UN GRUPO DE -C(=O)-R8, -C(=O)-O-R8, -C(=O)-NH2 O -C-(=O)-NH-R8; R8 ES ALQUILO (C1-C6), ALQUENILO (C3-C6) O CICLOALQUILO (C3-C6); R4 ES METILO O ETILO, O R3 Y R4 ESTAN UNIDOS ENTRE SI Y FORMAN UN GRUPO CONDENSADO DE FORMULA (a), DONDE * Y ** SON CADA UNO UNION EN LAS POSICIONES 5 Y 6 RESPECTIVAMENTE EN EL ANILLO DE DIHIDROPIRIMIDINA, R9 ES H, ALQUILO (C1-C6) O CICLOALQUILO (C3-C6); R5 ES H O ALQUILO (C1-C6), SUSTITUIDO OPCIONALMENTE CON CIANO, HIDROXILO, ALCOXI (C1-C4), ENTRE OTROS; R6 ES H, F O CL. SON COMPUESTOS PREFERIDOS: (4S)-4-[2-(CICLOBUTILSULFONIL)-4-CIANOFENIL]-3,6-DIMETIL-2-OXO-1[3-(TRIFLUOROMETIL)FENIL]-1,2,3,4-TETRAHIDROPIRIMIDINA-5-CARBONILO, (4S)-3-(CIANOMETIL)-4-[4-CIANO-2-(METILSULFONIL)FENIL]-6-METIL-2.OXO-1-[3-(TRIFLUOROMETIL)-FENIL]-1,2,3,4-TETRAHIDROPIRIMIDINA-5-CARBONITRILO, ENTRE OTROS. TAMBIEN SE REFIERE A UN METODO DE PREPARACION PARA UNA COMPOSICION FARMACEUTICA QUE LOS CONTIENE. DICHOS COMPUESTOS SON INHIBIDORES DE ELASTASA NEUTROFILA HUMANA (HNE), SIENDO DE UTILIDAD EN EL TRATAMIENTO DE TRASTORNOS PULMONARES Y DEL SISTEMA CARDIOVASCULAR TAL COMO HIPERTENSION ARTERIAL PULMONAR, ENTRE OTROS
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102007061766A DE102007061766A1 (de) | 2007-12-20 | 2007-12-20 | 4-(4-Cyano-2-thioaryl)-dihydropyrimidinone und ihre Verwendung |
DE102008022521A DE102008022521A1 (de) | 2008-05-07 | 2008-05-07 | 1,4-Diaryl-pyrimidopyridazin-2,5-dione und ihre Verwendung |
DE102008052013A DE102008052013A1 (de) | 2008-10-17 | 2008-10-17 | 4-(4-Cyano-2-thioaryl)-dihydropyrimidinone und ihre Verwendung |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20091429A1 true PE20091429A1 (es) | 2009-09-26 |
Family
ID=40394273
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2008002054A PE20091429A1 (es) | 2007-12-20 | 2008-12-11 | 4-(4-ciano-2-tioaril)dihidropirimidinonas como inhibidores de la elastasa neutrofila humana (hne) |
Country Status (39)
Country | Link |
---|---|
US (3) | US8288402B2 (es) |
EP (1) | EP2234985B1 (es) |
JP (1) | JP5519526B2 (es) |
KR (2) | KR101712786B1 (es) |
CN (2) | CN103204815B (es) |
AR (1) | AR069765A1 (es) |
AT (1) | ATE548355T1 (es) |
AU (1) | AU2008340733B9 (es) |
BR (1) | BRPI0821027B8 (es) |
CA (1) | CA2709786C (es) |
CL (1) | CL2008003691A1 (es) |
CO (1) | CO6280490A2 (es) |
CR (1) | CR11472A (es) |
CY (1) | CY1112813T1 (es) |
DK (1) | DK2234985T3 (es) |
DO (1) | DOP2010000165A (es) |
EC (1) | ECSP10010216A (es) |
ES (1) | ES2382143T3 (es) |
HK (2) | HK1146485A1 (es) |
HR (1) | HRP20120457T1 (es) |
IL (2) | IL205742A (es) |
JO (1) | JO2756B1 (es) |
MA (1) | MA31920B1 (es) |
MX (1) | MX2010006033A (es) |
MY (1) | MY150285A (es) |
NZ (1) | NZ586263A (es) |
PE (1) | PE20091429A1 (es) |
PL (1) | PL2234985T3 (es) |
PT (1) | PT2234985E (es) |
RS (1) | RS52270B (es) |
RU (1) | RU2497813C2 (es) |
SG (2) | SG186679A1 (es) |
SI (1) | SI2234985T1 (es) |
SV (1) | SV2010003581A (es) |
TN (1) | TN2010000288A1 (es) |
TW (1) | TWI455715B (es) |
UY (1) | UY31526A1 (es) |
WO (1) | WO2009080199A1 (es) |
ZA (1) | ZA201004239B (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008126920A1 (ja) * | 2007-04-11 | 2008-10-23 | Ajinomoto Co., Inc. | 糖尿病治療薬 |
MX2010006033A (es) * | 2007-12-20 | 2010-07-16 | Bayer Schering Pharma Ag | 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso. |
DE102009016553A1 (de) * | 2009-04-06 | 2010-10-07 | Bayer Schering Pharma Aktiengesellschaft | Sulfonamid- und Sulfoximin-substituierte Diaryldihydropyrimidinone und ihre Verwendung |
GB201004178D0 (en) * | 2010-03-12 | 2010-04-28 | Pulmagen Therapeutics Inflamma | Enzyme inhibitors |
GB201004179D0 (en) * | 2010-03-12 | 2010-04-28 | Pulmagen Therapeutics Inflamma | Enzyme inhibitors |
DE102010030187A1 (de) | 2010-06-16 | 2011-12-22 | Bayer Schering Pharma Aktiengesellschaft | 4-Cyan-2-sulfonylphenyl)pyrazolyl-substituierte Pyridinone und Pyrazinone und ihre Verwendung |
MX2014002285A (es) | 2011-08-26 | 2017-01-06 | Southern Res Inst | Inhibidores de la replicacion del vih. |
CN103373951B (zh) * | 2012-04-28 | 2016-03-09 | 上海医药工业研究院 | 一种拉帕替尼中间体的制备方法 |
US9815815B2 (en) | 2013-01-10 | 2017-11-14 | Pulmokine, Inc. | Non-selective kinase inhibitors |
US20140221335A1 (en) * | 2013-02-06 | 2014-08-07 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
US9115093B2 (en) | 2013-03-04 | 2015-08-25 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
EP3054937B1 (en) | 2013-10-11 | 2023-07-26 | Pulmokine, Inc. | Spray dry formulations |
USRE47493E1 (en) | 2014-02-20 | 2019-07-09 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
EP3126339A1 (de) | 2014-04-03 | 2017-02-08 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituierte cyclopentancarbonsäuren und ihre verwendung |
JP2017509665A (ja) | 2014-04-03 | 2017-04-06 | バイエル ファーマ アクチエンゲゼルシャフト | 気道疾患治療のための2,5−ジ置換されたシクロペンタンカルボン酸類 |
EP3126340A2 (de) | 2014-04-03 | 2017-02-08 | Bayer Pharma Aktiengesellschaft | Chirale 2,5-disubstituierte cyclopentancarbonsäure-derivate und ihre verwendung |
US9657015B2 (en) | 2014-07-31 | 2017-05-23 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
US9290457B2 (en) * | 2014-07-31 | 2016-03-22 | Boehringer Ingelheim International Gmbh | Substituted dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
US9458113B2 (en) * | 2014-07-31 | 2016-10-04 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
US9440930B2 (en) * | 2014-07-31 | 2016-09-13 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
US9475779B2 (en) * | 2014-07-31 | 2016-10-25 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
WO2016050835A2 (en) * | 2014-10-02 | 2016-04-07 | Ruprecht-Karls-Universität Heidelberg | Selective inhibitors of neutrophil elastase for treating neuropathic pain and chronic pain states harbouring a neuropathic component |
AU2016232270B2 (en) | 2015-03-18 | 2020-09-03 | Ph Pharma Co., Ltd. | Method for producing (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro pyrimidine-5-carbonitrile |
WO2016176399A1 (en) * | 2015-04-28 | 2016-11-03 | Stc.Unm | Compositions and methods for treatment of pulmonary hypertension |
US20190008867A1 (en) * | 2015-11-13 | 2019-01-10 | Ph Pharma Co., Ltd. | 4-(4-cyano-2-thioaryl)dihydropyrimidinones for treating chronic wounds |
JP2020500183A (ja) | 2016-10-27 | 2020-01-09 | プルモキネ、インコーポレイテッド | 肺高血圧症の治療のための併用療法 |
US9856232B1 (en) | 2017-06-20 | 2018-01-02 | King Saud University | Dihydropyrimidinone derivatives |
CA3101274A1 (en) * | 2018-04-24 | 2019-10-31 | Ph Pharma Co., Ltd. | Use of neutrophil elastase inhibitors in liver disease |
GB201820450D0 (en) | 2018-12-14 | 2019-01-30 | Z Factor Ltd | Compound and its use for the treatment of alpha1-antitryspin deficiency |
MX2022002054A (es) * | 2019-08-23 | 2022-08-08 | Ph Pharma Co Ltd | Uso de un inhibidor de la elastasa de neutrofilo en la enfermedad pulmonar. |
CN111978179A (zh) * | 2020-08-27 | 2020-11-24 | 青岛科技大学 | 一种6-羟基己酸酯的合成方法 |
WO2022076881A1 (en) * | 2020-10-09 | 2022-04-14 | The Regents Of The University Of California | Methods of treating alzheimer's disease using slow tight binding soluble epoxide hydrolase inhibitors |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUT42077A (en) * | 1985-06-03 | 1987-06-29 | Squibb & Sons Inc | Process for producing diesters of 2-tioxo- or 2-oxo-pyrimidine-1,5-dicarboxylic acid and 1-acyl-pyrimidine-5-carboxylic acids and esters |
US4738965A (en) * | 1987-02-03 | 1988-04-19 | Institut Organischskogo Sinteza Akademii Nauk Ssr | 2-oxo-4-(2'-difluoromethylthiophenyl)-5-methoxycarbonyl-6-methyl-1,2,3,4-tetrahydropyrimidine |
GB9214053D0 (en) | 1992-07-02 | 1992-08-12 | Ici Plc | Heterocyclic amides |
JP2000507545A (ja) * | 1996-03-25 | 2000-06-20 | スミスクライン・ビーチャム・コーポレイション | Cns損傷についての新規な治療 |
BR0013427A (pt) * | 1999-08-19 | 2002-07-30 | Nps Pharma Inc | Compostos heteropolicìclicos e seus usos como antagonistas no receptor de glutamato metabotrópico |
MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
GB0219896D0 (en) | 2002-08-27 | 2002-10-02 | Bayer Ag | Dihydropyridine derivatives |
GB2392910A (en) * | 2002-09-10 | 2004-03-17 | Bayer Ag | 2-Oxopyrimidine derivatives and their use as human leukocyte elastase inhibitors |
US7566723B2 (en) | 2002-09-10 | 2009-07-28 | Bayer Healthcare Ag | 1-phenyl1-3,4-dihydropyrimidin-2(1H)-one derivatives and their use |
PL375647A1 (en) * | 2002-09-10 | 2005-12-12 | Bayer Healthcare Ag | Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes |
US7166603B2 (en) | 2003-07-23 | 2007-01-23 | Bristol-Myers Squibb Co. | Dihydropyrimidone inhibitors of calcium channel function |
JP4825194B2 (ja) * | 2004-02-26 | 2011-11-30 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | 1,4−ジアリール−ジヒドロピリミジン−2−オン化合物およびヒト好中球エラスターゼ阻害剤としてのそれらの使用 |
WO2005082863A2 (en) * | 2004-02-26 | 2005-09-09 | Bayer Healthcare Ag | 1,4 diaryl-dihydropyrimidin-2 ones and their use as a human neutrophil elastase inhibitors |
JP2007530690A (ja) * | 2004-03-29 | 2007-11-01 | メルク エンド カムパニー インコーポレーテッド | 11−β−ヒドロキシステロイドデヒドロゲナーゼ−1の阻害剤としてのジアリールトリアゾール |
GB0502258D0 (en) | 2005-02-03 | 2005-03-09 | Argenta Discovery Ltd | Compounds and their use |
GB0512940D0 (en) | 2005-06-24 | 2005-08-03 | Argenta Discovery Ltd | Compounds and their use |
GB0520743D0 (en) | 2005-10-12 | 2005-11-23 | Argenta Discovery Ltd | Compounds and their use |
WO2007129060A1 (en) | 2006-05-04 | 2007-11-15 | Argenta Discovery Limited | Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors |
US20100010024A1 (en) | 2006-07-01 | 2010-01-14 | Bayer Healthcare Ag | Use of1,4-diaryl-dihydropyrimidine-2-on derivatives for treating pulmonary arterial hypertension |
EP2064184A1 (en) | 2006-09-04 | 2009-06-03 | AstraZeneca AB | Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors |
DE102008022521A1 (de) * | 2008-05-07 | 2009-11-12 | Bayer Schering Pharma Aktiengesellschaft | 1,4-Diaryl-pyrimidopyridazin-2,5-dione und ihre Verwendung |
MX2010006033A (es) * | 2007-12-20 | 2010-07-16 | Bayer Schering Pharma Ag | 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso. |
DE102009016553A1 (de) * | 2009-04-06 | 2010-10-07 | Bayer Schering Pharma Aktiengesellschaft | Sulfonamid- und Sulfoximin-substituierte Diaryldihydropyrimidinone und ihre Verwendung |
-
2008
- 2008-12-09 MX MX2010006033A patent/MX2010006033A/es active IP Right Grant
- 2008-12-09 EP EP08864824A patent/EP2234985B1/de active Active
- 2008-12-09 US US12/809,781 patent/US8288402B2/en active Active
- 2008-12-09 CA CA2709786A patent/CA2709786C/en active Active
- 2008-12-09 MY MYPI2010002687A patent/MY150285A/en unknown
- 2008-12-09 DK DK08864824.1T patent/DK2234985T3/da active
- 2008-12-09 KR KR1020167021839A patent/KR101712786B1/ko active IP Right Grant
- 2008-12-09 JP JP2010538407A patent/JP5519526B2/ja active Active
- 2008-12-09 KR KR1020107016069A patent/KR101649381B1/ko active Application Filing
- 2008-12-09 PL PL08864824T patent/PL2234985T3/pl unknown
- 2008-12-09 BR BRPI0821027A patent/BRPI0821027B8/pt active IP Right Grant
- 2008-12-09 RS RS20120213A patent/RS52270B/en unknown
- 2008-12-09 RU RU2010129724/04A patent/RU2497813C2/ru active
- 2008-12-09 AU AU2008340733A patent/AU2008340733B9/en active Active
- 2008-12-09 SG SG2012094132A patent/SG186679A1/en unknown
- 2008-12-09 PT PT08864824T patent/PT2234985E/pt unknown
- 2008-12-09 WO PCT/EP2008/010411 patent/WO2009080199A1/de active Application Filing
- 2008-12-09 SI SI200830619T patent/SI2234985T1/sl unknown
- 2008-12-09 CN CN201310122598.7A patent/CN103204815B/zh active Active
- 2008-12-09 ES ES08864824T patent/ES2382143T3/es active Active
- 2008-12-09 CN CN2008801216561A patent/CN101903356B/zh active Active
- 2008-12-09 AT AT08864824T patent/ATE548355T1/de active
- 2008-12-09 NZ NZ586263A patent/NZ586263A/en unknown
- 2008-12-09 SG SG10201604819TA patent/SG10201604819TA/en unknown
- 2008-12-11 CL CL2008003691A patent/CL2008003691A1/es unknown
- 2008-12-11 PE PE2008002054A patent/PE20091429A1/es active IP Right Grant
- 2008-12-11 UY UY31526A patent/UY31526A1/es active IP Right Grant
- 2008-12-15 AR ARP080105447A patent/AR069765A1/es active IP Right Grant
- 2008-12-18 JO JO2008569A patent/JO2756B1/en active
- 2008-12-19 TW TW097149556A patent/TWI455715B/zh not_active IP Right Cessation
-
2010
- 2010-05-13 IL IL205742A patent/IL205742A/en active IP Right Grant
- 2010-05-28 EC EC2010010216A patent/ECSP10010216A/es unknown
- 2010-06-02 CR CR11472A patent/CR11472A/es unknown
- 2010-06-02 SV SV2010003581A patent/SV2010003581A/es unknown
- 2010-06-02 DO DO2010000165A patent/DOP2010000165A/es unknown
- 2010-06-02 CO CO10066579A patent/CO6280490A2/es not_active Application Discontinuation
- 2010-06-15 ZA ZA2010/04239A patent/ZA201004239B/en unknown
- 2010-06-16 MA MA32921A patent/MA31920B1/fr unknown
- 2010-06-18 TN TN2010000288A patent/TN2010000288A1/fr unknown
-
2011
- 2011-01-21 HK HK11100646.5A patent/HK1146485A1/xx unknown
-
2012
- 2012-05-29 HR HRP20120457AT patent/HRP20120457T1/hr unknown
- 2012-05-31 CY CY20121100495T patent/CY1112813T1/el unknown
- 2012-09-12 US US13/612,435 patent/US8889700B2/en active Active
-
2013
- 2013-09-02 HK HK13110227.9A patent/HK1183018A1/xx unknown
-
2014
- 2014-10-23 US US14/522,510 patent/US9174997B2/en active Active
- 2014-11-18 IL IL235754A patent/IL235754A/en active IP Right Grant
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20091429A1 (es) | 4-(4-ciano-2-tioaril)dihidropirimidinonas como inhibidores de la elastasa neutrofila humana (hne) | |
AR047538A1 (es) | Piridazinonas como antagonistas de las integrinas alfa4 | |
AR050281A1 (es) | Derivados de indol, indazol e indazolina. procesos de obtencion y composiciones farmaceuticas | |
AR051092A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa | |
AR075597A1 (es) | Derivados de indol como antagonistas de receptores crth2, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del asma y otras enfermedades alergicas . | |
PE20051170A1 (es) | DERIVADOS DE PIRROL COMO INHIBIDORES DEL FACTOR Xa | |
UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. | |
AR054369A1 (es) | Compuestos de imidazol condensado y su uso como inhibidores de aldosterona sintasa | |
AR051202A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa | |
AR052866A1 (es) | Fenil-metanonas monociclicas sustituidas | |
AR049696A1 (es) | Derivados de indol | |
PE20060150A1 (es) | Antagonistas de cgrp seleccionados, composiciones farmaceuticas y procedimiento para su preparacion | |
AR052943A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
CO5640135A2 (es) | Derivados de 4-(4-(heterociclilalcoxi)-1-(heterociclil-carbonil)piperidina y compuestos relacionados como antagonistas de histamina h3 para el tratamiento de enfermedades neurologicas tales como alzheimer | |
PE20060589A1 (es) | FENILAMINOTIAZOLES SUSTITUIDOS COMO AGONISTAS DE ADENOSINA A1 Y A2b | |
PE20071156A1 (es) | COMPUESTOS DERIVADOS DE 4,5,6,7-TETRAHIDRO-1H-INDAZOL COMO POTENCIADORES DEL RECEPTOR DEL ACIDO a-AMINO-3-HIDROXI-5-METILISOXAZOL-4-PROPIONICO (AMPA) | |
PE20060777A1 (es) | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas | |
PE20081475A1 (es) | Arilamidas sustituidas por tiazol u oxazol | |
AR051638A1 (es) | Compuestos de piperidinilo y su uso para tratar desordenes de respuesta al bloqueo de los canales de calcio tipo n | |
AR079260A1 (es) | Inhibidores de bencimidazol de la produccion de leucotrienos, un procedimiento para su preparacion, composiciones farmaceuticas que los comprenden y su empleo como medicamentos en el tratamiento de trastornos mediados por leucotrienos | |
PE20060770A1 (es) | Derivados de n-[(4,5-difenil-3-alquil-2-tienil)metil]amina como antagonistas de los receptores cannabinoides cb1 | |
AR059328A1 (es) | Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp | |
AR068376A1 (es) | Amidas heterociclicas utiles para inhibir la via hedgehog. | |
PE20060273A1 (es) | Derivados de tetrahidroisoquinolilsulfonamidas como moduladores del receptor h3 | |
AR047958A1 (es) | Derivados de 1-bencil-5-piperazin-1-il-3,4 dihidro-1h-quinazolin-2-ona y sus derivados 1h-benzo(1,2,6)tiadiazina-2,2-dioxidos y 1,4-dihidro-benzo(d)(1,3)oxazinas-2-ona,como moduladores del receptor 5-ht,para el tratamiento de enfermedades del sistema nervioso central. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |